

**AMENDMENTS TO THE CLAIMS**

1. - 7. **(Canceled)**

8. (Currently amended) A ~~method of regeneration therapy for injured tissue~~ of localizing mesenchymal stem cells to an injury site, which comprises administering to a patient in need thereof mesenchymal stem cells and a mesenchymal stem cell migration-enhancing factor, thereby enhancing the migration and accumulation of the administered mesenchymal stem cells in the injured tissue or suppressing the diffusion of the administered mesenchymal stem cells from the injured tissue to enhance regeneration of the injured tissue,

wherein the mesenchymal stem cell migration-enhancing factor is selected from the group consisting of Epidermal Growth Factor (EGF), Heparin Binding Epidermal Growth Factor (HB-EGF), Transforming Growth Factor-alpha (TGF- $\alpha$ ),  $\alpha$ -thrombin, Platelet-Derived Growth Factor-AB (PDGF-AB), Platelet-Derived Growth Factor-BB (PDGF-BB), basic Fibroblast Growth Factor (bFGF), hyaluronic acid, Insulin-like Growth Factor-1 (IGF-1), and Hepatocyte Growth Factor (HGF).

9. **(Previously Presented)** The method according to claim 8, wherein the factor is administered simultaneously with, or continuously to, or separately from mesenchymal stem cells.

10. **Canceled**

11. **(Previously Presented)** The method according to claim 8, wherein the injured tissue results from osteoarthritis, bone fracture, loss of alveolar bone or jaw bone, cerebral infarction, myocardial infarction, or lower limb ischemia.

12. **Canceled**

13. **(Previously Presented)** The method according to claim 8, wherein the mesenchymal stem cell migration-enhancing factor is administered ~~topically to the injured tissue~~ to the injury site or the periphery thereof.

14. **(Previously Presented)** The method according to claim 8, wherein the mesenchymal stem cell migration-enhancing factor is administered by injection.

15. **(Currently amended)** The method according to ~~claim 13~~ claim 8, wherein the mesenchymal stem cell migration-enhancing factor is applied over the injured tissue.

16. **Canceled**

17. **(Previously Presented)** The method according to claim 8, wherein the mesenchymal stem cells are administered to the circulatory system and the mesenchymal stem cell migration-enhancing factor is administered by injection.

18. **(Currently amended)** The method according to claim 17, further comprising administering mesenchymal stem cells ~~topically~~ to the injured tissue or its periphery, before, after or simultaneously with the administration of the mesenchymal stem cell migration-enhancing factor.

19. **(Currently amended)** A method of ~~regeneration therapy for injured tissue~~ localizing mesenchymal stem cells to an injury site, which comprises administering to a patient in need thereof mesenchymal stem cells and a mesenchymal stem cell migration-enhancing factor, thereby enhancing the migration and accumulation of the administered mesenchymal stem cells in the injured tissue or suppressing the diffusion of the administered mesenchymal stem cells from the injured tissue to enhance regeneration of the injured tissue,

wherein the mesenchymal stem cell migration-enhancing factor is selected from the group consisting of Epidermal Growth Factor (EGF), Heparin Binding Epidermal Growth Factor (HB-EGF), Transforming Growth Factor-alpha (TGF- $\alpha$ ),  $\alpha$ -thrombin, Platelet-Derived Growth Factor-AB (PDGF-AB), Platelet-Derived Growth Factor-BB (PDGF-BB), basic Fibroblast Growth Factor (bFGF), hyaluronic acid, Insulin-like Growth Factor-1 (IGF-1), and Hepatocyte Growth Factor (HGF),

wherein the mesenchymal stem cell migration-enhancing factor is administered as a complex with atelocollagen by injection into the injured tissue.

20. (New) A method of localizing mesenchymal stem cells to an injury site, which comprises administering to a patient in need thereof mesenchymal stem cells and a mesenchymal stem cell migration-enhancing factor, thereby enhancing the migration and accumulation of the administered mesenchymal stem cells in the injured tissue or suppressing the diffusion of the administered mesenchymal stem cells from the injured tissue to enhance regeneration of the injured tissue,

wherein the mesenchymal stem cell migration-enhancing factor is selected from the group consisting of Epidermal Growth Factor (EGF), Heparin Binding Epidermal Growth Factor (HB-EGF), Transforming Growth Factor-alpha (TGF- $\alpha$ ),  $\alpha$ -thrombin, Platelet-Derived Growth Factor-AB (PDGF-AB), Platelet-Derived Growth Factor-BB (PDGF-BB), basic Fibroblast Growth Factor (bFGF), hyaluronic acid, Insulin-like Growth Factor-1 (IGF-1), and Hepatocyte Growth Factor (HGF),

wherein the mesenchymal stem cell migration-enhancing factor is administered by injection into the injured tissue.

21. (New) The method of claim 20, wherein the mesenchymal stem cell migration-enhancing factor is administered by injection of a transplant comprising said mesenchymal stem cell migration-enhancing factor.

22. (New) The method of claim 8, in which the growth factor is PDGF-BB.

23. (New) The method of claim 13, in which the growth factor is PDGF-BB.

24. (New) The method of claim 15, in which the growth factor is PDGF-BB.

25. (New) The method of claim 17, in which the growth factor is PDGF-BB.

26. (New) The method of claim 19, in which the growth factor is PDGF-BB.

27. (New) The method of claim 20, in which the growth factor is PDGF-BB.

28. (New) The method of claim 21, in which the growth factor is PDGF-BB.